News
RSLS
0.1694
-0.24%
-0.0004
Weekly Report: what happened at RSLS last week (0422-0426)?
Weekly Report · 50m ago
Weekly Report: what happened at RSLS last week (0415-0419)?
Weekly Report · 04/22 12:24
Weekly Report: what happened at RSLS last week (0408-0412)?
Weekly Report · 04/15 12:14
RESHAPE LIFESCIENCES - ON APRIL 9, RECEIVED WRITTEN NOTICE FROM NASDAQ STAFF THAT CO HAS NOT REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT
Reuters · 04/10 20:58
Weekly Report: what happened at RSLS last week (0401-0405)?
Weekly Report · 04/08 12:20
ReShape Lifesciences Tweets 'Will #GLP1 medications replace #weightloss #surgery? According to ReShape CEO, Paul Hickey, via @InvestingCom, #GLP1s are a very attractive tool to fight #obesity. However, our ReShape Lap-Band® is safe and less invasive'
Benzinga · 04/03 17:39
ReShape Lifesciences reports FY results
Seeking Alpha · 04/01 20:44
*ReShape Lifesciences 2023 R&D Expenses $2.3M >RSLS
Dow Jones · 04/01 20:13
*ReShape Lifesciences 2023 Rev $8.7M >RSLS
Dow Jones · 04/01 20:13
Reshape Lifesciences FY23 Sales $8.678M Miss $8.904M Estimate
Benzinga · 04/01 20:08
RESHAPE LIFESCIENCES INC - 2024 OPERATING EXPENSES EXPECTED TO DECREASE BY MORE THAN 50% COMPARED TO 2023
Reuters · 04/01 20:05
Press Release: ReShape Lifesciences(R) Reports -3-
GAAP net loss attributable to common stockholders for the years ended December 31, 2023 and 2022 is a reconciliation of net loss to adjusted EBITDA attributable to stockholders. The company's net loss is a non-GAAP measure of the difference between GAAP and non- GAAP net losses. The Company expects to report a net loss of $1.2 billion in the first quarter of 2022.
Dow Jones · 04/01 20:05
Press Release: ReShape Lifesciences(R) Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc. Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update Completed First Surgeries With Next-Generation Lap-Band(R) 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023. Conference Call to be Held at 4:30 pm ET today.
Dow Jones · 04/01 20:05
Weekly Report: what happened at RSLS last week (0325-0329)?
Weekly Report · 04/01 12:16
ReShape Lifesciences gets notice of allowance for additional U.S. patent
ReShape Lifesciences gets notice of allowance for additional U.S. Patent. The company has received a patent for an intragastric balloon system. Once issued, the patent will provide protection for at least till January 2031. RSLS +10.26% premarket to $0.1998.
Seeking Alpha · 03/28 12:56
Weekly Report: what happened at RSLS last week (0318-0322)?
Weekly Report · 03/25 12:19
Weekly Report: what happened at RSLS last week (0311-0315)?
Weekly Report · 03/18 12:18
Weekly Report: what happened at RSLS last week (0304-0308)?
Weekly Report · 03/11 12:12
ReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut plan
Healthcare ReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut plan. RSLS +3.9% premarket to $0.1807. Plan expected to prioritize commercialization of the company's enhanced Lap-Band 2.0 FLEX.
Seeking Alpha · 03/04 14:05
Weekly Report: what happened at RSLS last week (0226-0301)?
Weekly Report · 03/04 12:17
More
Webull provides a variety of real-time RSLS stock news. You can receive the latest news about Reshape Lifesciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RSLS
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.